Genome & Company (KOSDAQ:314130)
South Korea · Delayed Price · Currency is KRW 2,735.00
-20.00 (-0.73%)
At close: Sep 17, 2025
Genome & Company Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
Operating Revenue | 24,018 | 27,745 | 14,296 | 14,085 | 451.25 | 150.58 | Upgrade |
Other Revenue | -0 | -0 | - | -0 | - | - | Upgrade |
| 24,018 | 27,745 | 14,296 | 14,085 | 451.25 | 150.58 | Upgrade | |
Revenue Growth (YoY) | 0.39% | 94.07% | 1.50% | 3021.27% | 199.67% | 228.54% | Upgrade |
Cost of Revenue | 10,930 | 12,075 | 10,232 | 8,487 | 77.01 | - | Upgrade |
Gross Profit | 13,088 | 15,670 | 4,064 | 5,598 | 374.24 | 150.58 | Upgrade |
Selling, General & Admin | 23,935 | 22,025 | 28,677 | 19,664 | 14,123 | 12,915 | Upgrade |
Research & Development | 12,022 | 13,379 | 25,666 | 36,793 | 21,263 | 13,669 | Upgrade |
Operating Expenses | 40,364 | 39,869 | 59,156 | 63,110 | 36,461 | 26,779 | Upgrade |
Operating Income | -27,276 | -24,199 | -55,092 | -57,512 | -36,087 | -26,629 | Upgrade |
Interest Expense | -4,424 | -3,541 | -1,738 | -175 | -54.92 | -1,236 | Upgrade |
Interest & Investment Income | 3,216 | 3,778 | 4,121 | 850.8 | 458.17 | 112.52 | Upgrade |
Currency Exchange Gain (Loss) | -298.92 | -52.4 | -40.56 | -29.46 | -468.02 | 76.85 | Upgrade |
Other Non Operating Income (Expenses) | 5,652 | 4,206 | 3,252 | -1,112 | 161.16 | -3,418 | Upgrade |
EBT Excluding Unusual Items | -23,131 | -19,808 | -49,499 | -57,979 | -35,991 | -31,093 | Upgrade |
Gain (Loss) on Sale of Investments | -14.33 | 40.28 | 46.44 | -54.79 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -11.4 | -79.51 | -77.11 | 0.69 | -12.93 | -92.58 | Upgrade |
Asset Writedown | -8,367 | -8,367 | -2,325 | - | - | - | Upgrade |
Pretax Income | -33,687 | -28,215 | -51,855 | -58,033 | -36,004 | -31,186 | Upgrade |
Income Tax Expense | -692.2 | -1,365 | -1,202 | -1,083 | - | - | Upgrade |
Earnings From Continuing Operations | -32,995 | -26,850 | -50,653 | -56,950 | -36,004 | -31,186 | Upgrade |
Minority Interest in Earnings | 5,913 | 6,737 | 3,187 | 5,112 | 1,887 | 453.56 | Upgrade |
Net Income | -27,082 | -20,112 | -47,466 | -51,838 | -34,117 | -30,732 | Upgrade |
Net Income to Common | -27,082 | -20,112 | -47,466 | -51,838 | -34,117 | -30,732 | Upgrade |
Shares Outstanding (Basic) | 31 | 30 | 28 | 28 | 27 | 19 | Upgrade |
Shares Outstanding (Diluted) | 31 | 30 | 28 | 28 | 27 | 19 | Upgrade |
Shares Change (YoY) | 5.98% | 7.88% | 0.32% | 4.71% | 39.60% | 20.11% | Upgrade |
EPS (Basic) | -875.07 | -660.20 | -1680.81 | -1841.50 | -1269.10 | -1595.95 | Upgrade |
EPS (Diluted) | -875.42 | -660.20 | -1680.81 | -1841.50 | -1269.10 | -1596.00 | Upgrade |
Free Cash Flow | -20,447 | -20,301 | -51,077 | -50,399 | -29,034 | -19,662 | Upgrade |
Free Cash Flow Per Share | -660.67 | -666.38 | -1808.70 | -1790.39 | -1080.03 | -1021.03 | Upgrade |
Gross Margin | 54.49% | 56.48% | 28.43% | 39.74% | 82.94% | 100.00% | Upgrade |
Operating Margin | -113.56% | -87.22% | -385.37% | -408.34% | -7997.20% | -17683.84% | Upgrade |
Profit Margin | -112.76% | -72.49% | -332.02% | -368.05% | -7560.62% | -20409.23% | Upgrade |
Free Cash Flow Margin | -85.13% | -73.17% | -357.28% | -357.83% | -6434.20% | -13057.09% | Upgrade |
EBITDA | -19,817 | -16,752 | -46,820 | -48,051 | -33,496 | -25,164 | Upgrade |
EBITDA Margin | -82.51% | -60.38% | - | - | - | - | Upgrade |
D&A For EBITDA | 7,459 | 7,447 | 8,272 | 9,462 | 2,591 | 1,464 | Upgrade |
EBIT | -27,276 | -24,199 | -55,092 | -57,512 | -36,087 | -26,629 | Upgrade |
EBIT Margin | -113.56% | -87.22% | - | - | - | - | Upgrade |
Advertising Expenses | - | 3,803 | 2,033 | 1,505 | 987.32 | 207.99 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.